binds METTL1 to mediate KLK6 m7G methylation modification and promote the progression of colorectal cancer.
Colorectal cancer (CRC) is a major global health concern due to its high incidence and mortality rates.
APA
Zhang M, Li W, et al. (2026). binds METTL1 to mediate KLK6 m7G methylation modification and promote the progression of colorectal cancer.. iScience, 29(3), 114999. https://doi.org/10.1016/j.isci.2026.114999
MLA
Zhang M, et al.. " binds METTL1 to mediate KLK6 m7G methylation modification and promote the progression of colorectal cancer.." iScience, vol. 29, no. 3, 2026, pp. 114999.
PMID
41782829
Abstract
Colorectal cancer (CRC) is a major global health concern due to its high incidence and mortality rates. Understanding the underlying mechanisms of CRC proliferation, invasion, and metastasis is crucial for developing effective therapeutic strategies. Circular RNAs have emerged as important players in cancer development by regulating various cellular processes. N7-methylguanosine (m7G) modification has been shown to have important roles in gene expression regulation. In this study, we investigated the role of and its interaction with METTL1-mediated m7G modification in CRC development. We found that knocking down inhibited CRC cell proliferation, migration, and invasion. Further analyses revealed that interacts with METTL1 and regulates m7G modification levels in CRC cells. experiments showed that the combined application of knockdown and METTL1 knockdown achieved better tumor inhibitory effect. Our findings provide insights into the mechanism of CRC progression and present potential therapeutic targets for the treatment of CRC.
같은 제1저자의 인용 많은 논문 (5)
- Deep Learning-based Multiple Arterial Phase MRI: A Step toward Improved Hepatocellular Carcinoma Diagnosis.
- Artificial intelligence-driven pharmacovigilance analysis of polypharmacy and adverse events in breast cancer survivors treated with antidepressants.
- Explainable artificial intelligence for multi-modal cancer analysis: From genomics to immunology.
- pH and temperature dual-responsive covalent organic framework composites for efficient enrichment of phosphoproteins.
- Novel nanoparticle-combined therapy through EGFR and PD-L1 blockade: PFPR-siRNA-mediated suppressing NSCLC proliferation via PDT and enhanced antitumor immunity.